Medivation Inc  

(Public, NASDAQ:MDVN)   Watch this stock  
Find more results for MDVN
128.32
-0.55 (-0.43%)
May 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 126.94 - 130.13
52 week 68.31 - 141.58
Open 128.29
Vol / Avg. 526,591.00/886,694.00
Mkt cap 10.19B
P/E 37.35
Div/yield     -
EPS 3.44
Shares 78.69M
Beta 1.04
Inst. own 98%
Aug 5, 2015
Q2 2015 Medivation Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 16, 2015
Medivation Inc Annual Shareholders Meeting - 11:30AM EDT - Add to calendar
May 18, 2015
Medivation Inc at UBS Global Healthcare Conference
May 7, 2015
Q1 2015 Medivation Inc Earnings Call - Webcast
May 7, 2015
Q1 2015 Medivation Inc Earnings Release
Mar 10, 2015
Medivation Inc at Barclays Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -2.41% 38.91%
Operating margin 0.44% 39.67%
EBITD margin - 40.41%
Return on average assets -1.36% 42.39%
Return on average equity -2.72% 105.07%
Employees 485 -
CDP Score - -

Address

525 Market St Fl 36
SAN FRANCISCO, CA 94105-2747
United States - Map
+1-415-5433470 (Phone)
+1-415-5433411 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Medivation, Inc. is a biopharmaceutical company focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company selects technologies for development that can enter human studies within 12-18 months. It develops technologies without regard to therapeutic indication or therapeutic modality, such as small molecules, biologics and medical devices. The Company is engaged in various clinical trials. The Company’s PROSPER is a Phase III clinical trial. The Company’s TERRAIN trial and the STRIVE trial are two randomized, double-blind Phase II trials evaluating enzalutamide head-to-head versus bicalutamide in pre-chemotherapy CRPC patients. The Company’s PLATO is a Phase IV clinical trial. The Company and Astellas expanded the clinical development of enzalutamide to include breast cancer as a new indication.

Officers and directors

Kim D. Blickenstaff Independent Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
David T. Hung M.D. President, Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Richard A Bierly Chief Financial Officer, Principal Financial and Accounting Officer
Age: 59
Bio & Compensation  - Reuters
Stephen M. Kelsey M.D. Senior Vice President - New Projects
Age: 53
Bio & Compensation  - Reuters
Jennifer J. Rhodes Chief Compliance Officer, General Counsel, Corporate Secretary
Age: 44
Bio & Compensation  - Reuters
Dawn Svoronos Interim Chief Commercial Officer, Director
Age: 61
Bio & Compensation  - Reuters
Lynn Seely M.D. Chief Medical Officer
Age: 55
Bio & Compensation  - Reuters
C. Patrick Machado J.D. Director
Age: 51
Bio & Compensation  - Reuters
Kathryn E. Falberg Independent Director
Age: 54
Bio & Compensation  - Reuters
W. Anthony Vernon Independent Director
Age: 59
Bio & Compensation  - Reuters